|
Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study. |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Neurological institute BESDA (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche/Genentech |
Expert Testimony - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; GlaxoSmithKline; Novartis; Pfizer |
|
|
Speakers' Bureau - Amgen; Merck Serono; Roche Pharma AG; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Merck Serono; MSD Oncology |
|
|
|
Research Funding - Roche Pharma AG |
|
|
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Merck; Pfizer; Roche Pharma AG |